Legend Biotech's Q4 2025 Earnings Call Highlights: A Year of Milestones for CARVYKTI and Beyond
Legend Biotech, a leading cell therapy company, has made significant strides in the fourth quarter of 2025, according to its recent earnings call. The company reported strong sales and profitability numbers, with CARVYKTI net trade sales reaching $555 million, a 66% increase year-over-year.
The success of CARVYKTI, Legend Biotech's flagship CAR T-cell therapy for multiple myeloma, has been nothing short of remarkable. With over 10,000 patients worldwide choosing to be treated with the drug, it has brought hope to those struggling with this debilitating disease. The company's manufacturing facilities are now capable of producing 10,000 doses annually across all its manufacturing nodes.
CARVYKTI's impact extends beyond sales figures, however. It has set new standards for survival outcomes in relapsed refractory multiple myeloma and has a 97% overall manufacturing success rate. The drug is now offered in 14 global markets, making it the strongest CAR T launch to date.
The company also highlighted its commitment to innovation, with presentations at major medical conferences showcasing compelling data on CARVYKTI's efficacy and manufacturing success. Notably, new long-term CARVYKTI data demonstrated durable responses in key subgroups and reinforced the improved outcomes associated with earlier treatment with CARVYKTI.
One of the most significant milestones was achieved by triple class-exposed multiple myeloma patients who received a single infusion of CARVYKTI. This group, which had three prior lines of therapy, achieved a median PFS (progression-free survival) of 50.4 months, one of the longest PFS outcomes for BCMA-targeting CAR T therapy.
Legend Biotech's CEO, Ying Huang, expressed optimism about the company's future prospects, stating that they are poised to achieve company-wide profitability in 2026. The company is also expanding its presence globally, with a focus on becoming a fully scaled CAR T leader this year.
